Part I Basic Topics |
|
|
|
1 | (9) |
|
Pharmacoeconomics-What Is It? |
|
|
1 | (1) |
|
Why Is Pharmacoeconomics Important? |
|
|
2 | (1) |
|
Relationship of Pharmacoeconomics to Other Research |
|
|
3 | (1) |
|
Types of Pharmacoeconomic Studies |
|
|
4 | (4) |
|
|
8 | (1) |
|
|
8 | (1) |
|
|
8 | (1) |
|
|
9 | (1) |
|
Chapter 2 Measuring and Estimating Costs |
|
|
10 | (16) |
|
|
10 | (1) |
|
|
11 | (2) |
|
Alternative Method of Categorization |
|
|
13 | (1) |
|
|
13 | (1) |
|
Timing Adjustments for Costs |
|
|
14 | (4) |
|
Resources for Cost Estimations |
|
|
18 | (3) |
|
|
21 | (3) |
|
|
24 | (1) |
|
|
24 | (1) |
|
|
25 | (1) |
|
Chapter 3 Critiquing Research Articles |
|
|
26 | (9) |
|
Appropriateness of Methods of Analysis |
|
|
26 | (1) |
|
Questions to Use When Critiquing Research Articles |
|
|
26 | (6) |
|
|
32 | (1) |
|
|
32 | (1) |
|
|
33 | (1) |
|
|
34 | (1) |
|
Chapter 4 Cost-Minimization Analysis |
|
|
35 | (10) |
|
|
35 | (1) |
|
|
36 | (6) |
|
Composite Article: CMA-Anti-nausea |
|
|
37 | (5) |
|
|
42 | (2) |
|
|
44 | (1) |
|
|
44 | (1) |
|
Chapter 5 Cost-Effectiveness Analysis A |
|
|
A5 | |
|
|
45 | (1) |
|
Presentation of Costs and Effectiveness |
|
|
46 | (1) |
|
|
47 | (2) |
|
|
49 | (1) |
|
Intermediate Outcomes versus Primary Outcomes |
|
|
50 | (3) |
|
Efficacy versus Effectiveness |
|
|
53 | (1) |
|
|
54 | (1) |
|
|
55 | (15) |
|
Composite Article 1: CEA-Asthma |
|
|
55 | (8) |
|
Composite Article 2: CEA-Post-Myocardial Infarction Heart Failure |
|
|
63 | (7) |
|
|
70 | (1) |
|
|
71 | (1) |
|
|
71 | (1) |
|
Chapter 6 Cost-Utility Analysis |
|
|
72 | (31) |
|
|
72 | (1) |
|
Steps in Calculating QALYs |
|
|
73 | (7) |
|
|
80 | (5) |
|
|
85 | (14) |
|
Composite Article 1: CUA-Oncology |
|
|
85 | (7) |
|
Composite Article 2: CUA-Immunosuppression |
|
|
92 | (7) |
|
|
99 | (2) |
|
|
101 | (1) |
|
|
102 | (1) |
|
Chapter 7 Cost-Benefit Analysis |
|
|
103 | (28) |
|
|
103 | (1) |
|
Advantages and Disadvantages of Cost-Benefit Analysis |
|
|
104 | (1) |
|
|
105 | (1) |
|
Difference between Costs and Benefits |
|
|
106 | (1) |
|
Measuring Indirect and Intangible Benefits |
|
|
106 | (6) |
|
Calculating Results of Costs and Benefits |
|
|
112 | (2) |
|
|
114 | (14) |
|
Composite Article 1: CBA-Vaccination |
|
|
117 | (6) |
|
Composite Article 2: CBA-Alzheimer's Disease |
|
|
123 | (5) |
|
|
128 | (1) |
|
|
129 | (1) |
|
|
130 | (1) |
|
Chapter 8 Health-Related Quality of Life: Health Status Measures |
|
|
131 | (38) |
|
|
132 | (1) |
|
HRQoL Measures versus Utility Measures |
|
|
132 | (4) |
|
|
136 | (2) |
|
Assessing HRQoL Instruments |
|
|
138 | (3) |
|
Pharmacoeconomics and HRQoL Measures |
|
|
141 | (1) |
|
Preference-Based Classification Systems |
|
|
141 | (2) |
|
Patient-Reported Outcomes |
|
|
143 | (1) |
|
|
144 | (17) |
|
Composite Article 1: HRQoL-Rheumatoid Arthritis |
|
|
144 | (8) |
|
Composite Article 2: HRQoL-Chronic Low Back Pain |
|
|
152 | (9) |
|
|
161 | (4) |
|
|
165 | (1) |
|
|
166 | (3) |
Part II Advanced Topics |
|
|
Chapter 9 Decision Analysis |
|
|
169 | (24) |
|
What Is Decision Analysis? |
|
|
169 | (1) |
|
Steps in Decision Analysis |
|
|
169 | (6) |
|
|
175 | (2) |
|
|
177 | (14) |
|
Composite Article 1: Decision Analysis-Migraine |
|
|
178 | (7) |
|
Composite Article 2: Decision Analysis-Erectile Dysfunction |
|
|
185 | (6) |
|
|
191 | (1) |
|
|
192 | (1) |
|
|
192 | (1) |
|
Chapter 10 Markov Modeling |
|
|
193 | (32) |
|
|
193 | (1) |
|
|
193 | (7) |
|
Disadvantages of Markov Modeling |
|
|
200 | (1) |
|
|
201 | (1) |
|
|
202 | (1) |
|
|
203 | (9) |
|
Composite Article 1: Markov Modeling-Initiation of HIV Therapy |
|
|
204 | (8) |
|
|
212 | (8) |
|
Composite Article 2: Markov Modeling-Phosphate Binders |
|
|
213 | (7) |
|
|
220 | (1) |
|
|
221 | (2) |
|
|
223 | (1) |
|
|
224 | (1) |
|
Chapter 11 Retrospective Databases |
|
|
225 | (21) |
|
Overview of Retrospective Databases |
|
|
225 | (1) |
|
Randomized, Controlled Trials |
|
|
225 | (1) |
|
|
226 | (1) |
|
Advantages and Disadvantages of RCTs |
|
|
226 | (1) |
|
Advantages and Disadvantages of Observational Studies |
|
|
227 | (1) |
|
Types of Retrospective Databases |
|
|
228 | (2) |
|
Insurance and Claims Records |
|
|
230 | (1) |
|
Critiquing Retrospective Database Studies |
|
|
230 | (2) |
|
|
232 | (12) |
|
Composite Article 1: Retrospective Database-COPD |
|
|
232 | (8) |
|
Composite Article 2: Retrospective Database-Bisphosphonotes |
|
|
240 | (4) |
|
|
244 | (1) |
|
|
244 | (1) |
|
|
245 | (1) |
|
Chapter 12 Pharmacy Services |
|
|
246 | (18) |
|
What Are Pharmacy Services? |
|
|
246 | (1) |
|
History of Pharmacy Services |
|
|
247 | (1) |
|
|
247 | (2) |
|
Issues in Valuing Pharmacy Services |
|
|
249 | (1) |
|
Medicare Medication Therapy Management |
|
|
250 | (2) |
|
|
252 | (8) |
|
Composite Article: Pharmacy Services |
|
|
253 | (7) |
|
|
260 | (2) |
|
|
262 | (1) |
|
|
263 | (1) |
|
Chapter 13 International Perspective |
|
|
264 | (11) |
|
|
264 | (2) |
|
Comparability of Pharmacoeconomic Results between Countries |
|
|
266 | (1) |
|
History of Pharmacoeconomic Guideline Development |
|
|
266 | (5) |
|
|
271 | (1) |
|
|
271 | (2) |
|
|
273 | (1) |
|
|
274 | (1) |
|
|
275 | (8) |
|
Application of Pharmacoeconomics in the United States |
|
|
275 | (1) |
|
|
275 | (1) |
|
Private Health Care Plans |
|
|
276 | (1) |
|
Barriers to Pharmacoeconomics in the United States |
|
|
277 | (1) |
|
|
278 | (1) |
|
|
279 | (1) |
|
|
280 | (1) |
|
|
280 | (2) |
|
|
282 | (1) |
Glossary |
|
283 | (6) |
Index |
|
289 | |